Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 32Radiotherapy 11Bevacizumab 10Surgical Procedures, Operative 7IL13-PE38 7TIC10 compound 6Lomustine 6Carboplatin 6Radiation 5Chlorotoxin 5vorasidenib 4trametinib 4dabrafenib 4Valacyclovir 4OKN 007 4Flucytosine 4Dianhydrogalactitol 4Cyclophosphamide 4vocimagene amiretrorepvec 3abemaciclib 3Paclitaxel 3Nivolumab 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3CLR1404 3trans-sodium crocetinate 2pembrolizumab 2olutasidenib 2marizomib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Glioma × Genetic Therapy × Clear all
NCT01156584 2018-05-21

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma

Tocagen Inc.

Phase 1 Completed
54 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡